An interventional study of Quadro-Iliac Plane Block (QIPB) and Erector Spinae Plane Block in Postoperative Pain and Hip Arthroplasty, Total, sponsored by Uludag University. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Uludag University · Not applicable, Interventional, and Treatment
This prospective, single-center, randomized controlled, double-blind (participant and outcomes assessor) trial compares ultrasound-guided erector spinae plane block (ESPB) and quadro-iliac plane block (QIPB) in adult patients undergoing elective primary unilateral total hip arthroplasty (THA) under spinal anesthesia. Eighty patients will be randomized 1:1 to receive either block in addition to a standardized multimodal analgesia protocol. The primary outcome is cumulative opioid consumption (intravenous morphine equivalents, mg) during the first 24 postoperative hours. Secondary outcomes include quality of recovery (QoR-15), pain scores, opioid consumption at later time points, quadriceps strength, mobilization, patient satisfaction, and safety outcomes. It is hypothesized that QIPB will reduce 24-hour opioid consumption more than ESPB.
Rationale: Fascial plane blocks combined with spinal anesthesia are an important component of multimodal analgesia after total hip arthroplasty. ESPB has shown analgesic efficacy after THA in randomized trials. QIPB, described in 2024, may reach the lumbar plexus branches that contribute to hip innervation more consistently. To the investigators' knowledge, the two blocks have not been directly compared in THA.
Design: Prospective, single-center, randomized, double-blind (participant and outcomes assessor), parallel two-arm trial. Eighty adults (40 per group) undergoing elective primary unilateral THA under spinal anesthesia are allocated 1:1 (blocks of four, sealed opaque envelopes) to ultrasound-guided QIPB or ESPB, each with 30 mL of 0.25% bupivacaine, performed before incision. All patients receive standardized multimodal analgesia (dexamethasone, paracetamol, tenoxicam) and morphine patient-controlled analgesia (PCA) for rescue.
Assessments: Opioid consumption (PCA records, converted to IV morphine equivalents), NRS pain scores at rest and with movement, quadriceps strength, QoR-15 (preoperatively and at 24 hours), mobilization, satisfaction and adverse events are recorded for 48 hours. Postoperative hour 0 is the end of surgery.
Sample size and analysis: 37 patients per group are needed to detect an effect size of about 0.66 (alpha 0.05, two-sided, 80% power; G*Power 3.1.9.7); 40 per group are enrolled to allow for data loss. The primary analysis (modified intention-to-treat) uses the independent samples t-test or Mann-Whitney U test with the effect size and 95% confidence interval; repeated NRS scores are analyzed with a linear mixed-effects model, and secondary outcomes are exploratory. Analyses are performed with IBM SPSS Statistics.
Safety and oversight: The total bupivacaine dose will not exceed 2.5 mg/kg, and lipid emulsion is available in the operating room. Serious adverse events are reported to the ethics committee. A qualified person or team appointed by the principal investigator monitors the study. Participant data are coded and protected under the Turkish Personal Data Protection Law (No. 6698). The study is academic, with no external funding.
5,640 studies on the registry are indexed under Pain, Postoperative; 1,230 are open to participants now.
This study's planned enrollment of 80 is close to the median of 75 across 4,821 interventional studies indexed under Pain, Postoperative.
Browse Pain, Postoperative studies →Uludag University is the lead sponsor of 149 studies on the registry; 42 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: Quadro-Iliac Plane Block (QIPB)
Procedure: Erector Spinae Plane Block
Spinal anesthesia, then single-shot ultrasound-guided fascial plane block performed at the level of the iliac crest in the posterior plane of the quadratus lumborum muscle, with injection of 30 mL of 0.25% bupivacaine. Standard multimodal analgesia and morphine patient-controlled analgesia (PCA) are provided postoperatively.
Spinal anesthesia, then single-shot ultrasound-guided lumbar erector spinae plane block targeting the L3 vertebral level, with injection of 30 mL of 0.25% bupivacaine. Standard multimodal analgesia and morphine PCA are provided postoperatively.
Cumulative opioid consumption in the first 24 postoperative hours
Total opioid consumption (PCA and additional rescue morphine), determined from PCA device records and converted to intravenous morphine equivalents (mg).
Time frame: First 24 hours after surgery
Quality of Recovery-15 (QoR-15) score
The Quality of Recovery-15 (QoR-15) is a validated patient-reported measure of the quality of recovery after surgery and anesthesia. It has 15 items, each scored from 0 to 10, giving a total score of 0 to 150; higher scores indicate better recovery. The items cover five dimensions: physical comfort, physical independence, psychological support, emotional state and pain, and negative items are reverse-scored. Total scores are commonly interpreted as excellent (136-150), good (122-135), moderate (90-121) or poor (0-89). The validated Turkish version is used. It is administered preoperatively (baseline) and at postoperative hour 24; the outcome is the total score at hour 24 and its change from the preoperative baseline value.
Time frame: Postoperative 24th hour
Pain intensity at rest (Numeric Rating Scale, NRS)
The Numeric Rating Scale (NRS) is a validated, self-reported measure of pain intensity. Patients rate their pain on an 11-point scale from 0 (no pain) to 10 (unbearable pain); higher scores indicate more severe pain. Pain at rest is recorded at each time point listed in the time frame.
Time frame: PACU arrival and postoperative hours 2, 6, 12, 24, 36 and 48
Pain intensity with movement (Numeric Rating Scale, NRS)
The Numeric Rating Scale (NRS) is a validated, self-reported measure of pain intensity. Patients rate their pain on an 11-point scale from 0 (no pain) to 10 (unbearable pain); higher scores indicate more severe pain. Pain with movement is assessed during passive 45-degree flexion of the operated hip at each time point listed in the time frame.
Time frame: PACU arrival and postoperative hours 2, 6, 12, 24, 36 and 48
Time to first rescue analgesia
Time from the end of surgery to the first PCA request.
Time frame: First 48 hours after surgery
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.
Of 2,089 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 12 months is close to that.
Counting every sponsor, half of 2,102 studies reached it within 11 months; a quarter within 6 and three quarters within 23.
Completion moved once since we started tracking on Sep 25, 2026: Nov 2027 → Oct 2027, on Nov 3, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.